Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Richard Kones. (2013) Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vascular Health and Risk Management 9, pages 617-670.
Read now
Read now
Terry A Jacobson, Peter H Jones & Eli M Roth. (2010) Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety. Clinical Lipidology 5:5, pages 627-649.
Read now
Read now
Peter P Toth, Alberico Catapano, Joanne E Tomassini & Andrew M Tershakovec. (2010) Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clinical Lipidology 5:5, pages 655-684.
Read now
Read now
Mark J Cziraky & Tyan Thomas. (2010) Attainment of combined optimal lipid values: a paradigm shift in the management of dyslipidemia. Clinical Lipidology 5:4, pages 527-541.
Read now
Read now
Scott L. Charland & Daniel C. Malone. (2010) Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Current Medical Research and Opinion 26:2, pages 365-375.
Read now
Read now
Peter Jones. (2009) Fenofibric acid plus statin combination therapy for the treatment of mixed dyslipidemia. Clinical Lipidology 4:6, pages 699-711.
Read now
Read now
Sanjeev Balu, Robert J. Simko, Ralph M. Quimbo & Mark J. Cziraky. (2009) Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Current Medical Research and Opinion 25:11, pages 2765-2775.
Read now
Read now
Harold E Bays, David Neff, Joanne E Tomassini & Andrew M Tershakovec. (2008) Ezetimibe: cholesterol lowering and beyond. Expert Review of Cardiovascular Therapy 6:4, pages 447-470.
Read now
Read now
Ralph A Quimbo, Robert J Simko, Mark J Cziraky & Russel T Burge. (2008) Attainment of combined optimal lipid values and the impact of lipid medication on cardiovascular outcomes and costs in a commercially insured population in the US. Journal of Medical Economics 11:3, pages 449-470.
Read now
Read now
Articles from other publishers (30)
Rafael Perera, Emily McFadden, Julie McLellan, Tom Lung, Philip Clarke, Teresa Pérez, Thomas Fanshawe, Andrew Dalton, Andrew Farmer, Paul Glasziou, Osamu Takahashi, John Stevens, Les Irwig, Jennifer Hirst, Sarah Stevens, Asuka Leslie, Sachiko Ohde, Gautam Deshpande, Kevin Urayama, Brian Shine & Richard Stevens. (2015) Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. Health Technology Assessment 19:100, pages 1-402.
Crossref
Crossref
Andrea László, László Kalabay & János Nemcsik. (2013) Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: contradictions between the two main therapeutic pathways. BMC Research Notes 6:1.
Crossref
Crossref
Maria Cecília Bueno Jayme Gallani, Marilia Estevam Cornélio, Rúbia de Freitas Agondi & Roberta Cunha Matheus Rodrigues. (2013) Conceptual framework for research and clinical practice concerning cardiovascular health-related behaviors. Revista Latino-Americana de Enfermagem 21:spe, pages 207-215.
Crossref
Crossref
Hae Sun Suh, Joel W. Hay, Kathleen A. Johnson & Jason N. Doctor. (2012) Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias. Pharmacoepidemiology and Drug Safety 21:5, pages 470-484.
Crossref
Crossref
Keith C. Ferdinand, Michael H. Davidson, Maureen T. Kelly & Carolyn M. Setze. (2012) One-Year Efficacy and Safety of Rosuvastatin + Fenofibric Acid Combination Therapy in Patients with Mixed Dyslipidemia. American Journal Cardiovascular Drugs 12:2, pages 117-125.
Crossref
Crossref
G.A. Spinelli, C.R. Felipe, S.I. Park, E.L. Mandia-Sampaio, H. Tedesco-SilvaJrJr & J.O. Medina-Pestana. (2011) Lipid Profile Changes During the First Year After Kidney Transplantation: Risk Factors and Influence of the Immunosuppressive Drug Regimen. Transplantation Proceedings 43:10, pages 3730-3737.
Crossref
Crossref
M. J. Cziraky, H. Tan, M. F. Bullano, J. Yu, R. Schiebinger & V. J. Willey. (2011) Impact of optimal lipid value achievement between 2005 and 2009 in patients with mixed dyslipidaemia on cardiovascular event rates. International Journal of Clinical Practice 65:4, pages 425-435.
Crossref
Crossref
Győző Dani, László Márk & András Katona. (2011) Complex lipid-lowering treatment options in patients with a history of acute coronary syndrome. Orvosi Hetilap 152:8, pages 296-302.
Crossref
Crossref
Christie M. Ballantyne, Peter H. Jones, Maureen T. Kelly, Carolyn M. Setze, Aditya Lele, Kamlesh M. Thakker & James C. Stolzenbach. (2011) Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides. Cardiovascular Drugs and Therapy 25:1, pages 59-67.
Crossref
Crossref
Jesús Millán Núñez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Salas, Antonio Hernández Mijares, Vincent J. Carey, Michel P. Hermans, Frank M. Sacks & Jean-Charles Fruchart. (2011) Estudio REALIST (REsiduAl risk, LIpids and Standard Therapies): Un análisis del Riesgo Residual dependiente del perfil lipídico en el síndrome coronario agudo. Endocrinología y Nutrición 58:1, pages 38-47.
Crossref
Crossref
Jesús Millán Núñez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Salas, Antonio Hernández Mijares, Vincent J. Carey, Michel P. Hermans, Frank M. Sacks & Jean-Charles Fruchart. (2011) The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome. Endocrinología y Nutrición (English Edition) 58:1, pages 38-47.
Crossref
Crossref
Carl J. Pepine, Terry A. Jacobson, Dawn M. Carlson, Maureen T. Kelly, Carolyn M. Setze, Alex Gold, James C. Stolzenbach & Laura A. Williams. (2010) Combination Rosuvastatin Plus Fenofibric Acid in a Cohort of Patients 65 Years or Older With Mixed Dyslipidemia: Subanalysis of Two Randomized, Controlled Studies. Clinical Cardiology 33:10, pages 609-619.
Crossref
Crossref
Eli M. Roth, James M. McKenney, Maureen T. Kelly, Carolyn M. Setze, Dawn M. Carlson, Alex Gold, James C. Stolzenbach, Laura A. Williams & Peter H. Jones. (2010) Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia. American Journal Cardiovascular Drugs 10:3, pages 175-186.
Crossref
Crossref
M. John Chapman, Jan S. Redfern, Mark E. McGovern & Philippe Giral. (2010) Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics 126:3, pages 314-345.
Crossref
Crossref
Venkata M. Alla, Manu Kaushik & Aryan Mooss. (2010) Targeting Residual Risk: The Rationale for the Use of Non-HDL Cholesterol. Southern Medical Journal 103:5, pages 434-439.
Crossref
Crossref
Peter H. Jones, Kenneth Cusi, Michael H. Davidson, Maureen T. Kelly, Carolyn M. Setze, Kamlesh Thakker, Darryl J. Sleep & James C. Stolzenbach. (2010) Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus. American Journal Cardiovascular Drugs 10:2, pages 73-84.
Crossref
Crossref
Mark S. Kipnes, Eli M. Roth, James M. Rhyne, Carolyn M. Setze, Aditya Lele, Maureen T. Kelly, Darryl J. Sleep & James C. Stolzenbach. (2010) Year Two Assessment of Fenofibric Acid and Moderate-Dose Statin Combination. Clinical Drug Investigation 30:1, pages 51-61.
Crossref
Crossref
P. J. Marangos, L. J. Okamoto & J. J. Caro. 2010. Handbook of Disease Burdens and Quality of Life Measures. Handbook of Disease Burdens and Quality of Life Measures
1135
1149
.
Dan C. MalonePh.D.Ph.D., Denise M. BoudreauPh.D.Ph.D., Greg A. NicholsPh.D.Ph.D., Marsha A. RaebelPharm.D.Pharm.D., Paul A. FishmanPh.D.Ph.D., Adrianne C. FeldsteinM.D., M.P.M.D., M.P., Rami H. Ben-JosephPh.D.Ph.D., Lynn J. OkamotoPharm.D.Pharm.D., Audra N. BoscoePh.D.Ph.D. & David J. MagidM.D., M.P.M.D., M.P.. (2009) Association of Cardiometabolic Risk Factors and Prevalent Cardiovascular Events. Metabolic Syndrome and Related Disorders 7:6, pages 585-594.
Crossref
Crossref
Adam B. PolisM.A.M.A., Nicola AbateM.A.M.A., Alberico L. CatapanoPh.D.Ph.D., Christie M. BallantyneM.D.M.D., Michael H. DavidsonM.D.M.D., Steven S. SmugarM.D.M.D. & Andrew M. TershakovecM.D., M.P.M.D., M.P.. (2009) Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified by National Cholesterol Education Program Risk Category. Metabolic Syndrome and Related Disorders 7:6, pages 601-610.
Crossref
Crossref
Diana R. Chirovsky, Veronika Fedirko, Yadong Cui, Vasilisa Sazonov & Philip Barter. (2009) Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. European Journal of Cardiovascular Prevention & Rehabilitation 16:4, pages 404-423.
Crossref
Crossref
Xiao Xia Li, Jian Ping Liu, Jin Quan Cheng, Sheng Hong Han, Yi Jie Geng, Sheng Wei, Shi Tong Gao, Da Na Huang & Shao Fa Nie. (2008) Intercellular adhesion molecule-1 gene K469E polymorphism and ischemic stroke: a case-control study in a Chinese population. Molecular Biology Reports 36:6, pages 1565-1571.
Crossref
Crossref
A.I. Hatzitolios, V.G. Athyros, A. Karagiannis, C. Savopoulos, C. Charalambous, G. Kyriakidis, Th. Milidis, C. Papathanakis, A. Bitli, I. Vogiatsis, G. Ntaios, N. Katsiki, A. Symeonidis, K. Tziomalos & D.P. Mikhailidis. (2009) Implementation of strategy for the management of overt dyslipidemia: The IMPROVE-dyslipidemia study. International Journal of Cardiology 134:3, pages 322-329.
Crossref
Crossref
Peter H. Jones, Michael H. Davidson, Moti L. Kashyap, Maureen T. Kelly, Susan M. Buttler, Carolyn M. Setze, Darryl J. Sleep & James C. Stolzenbach. (2009) Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study. Atherosclerosis 204:1, pages 208-215.
Crossref
Crossref
Peter H. Jones, Michael H. Davidson, Anne C. Goldberg, Carl J. Pepine, Maureen T. Kelly, Susan M. Buttler, Carolyn M. Setze, Aditya Lele, Darryl J. Sleep & James C. Stolzenbach. (2009) Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies. Journal of Clinical Lipidology 3:2, pages 125-137.
Crossref
Crossref
Anne C. Goldberg, Harold E. Bays, Christie M. Ballantyne, Maureen T. Kelly, Susan M. Buttler, Carolyn M. Setze, Darryl J. Sleep & James C. Stolzenbach. (2009) Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia. The American Journal of Cardiology 103:4, pages 515-522.
Crossref
Crossref
Syed M. Mohiuddin, Carl J. Pepine, Maureen T. Kelly, Susan M. Buttler, Carolyn M. Setze, Darryl J. Sleep & James C. Stolzenbach. (2009) Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study. American Heart Journal 157:1, pages 195-203.
Crossref
Crossref
Scott L. Charland, Mark J. Cziraky, Ralph Quimbo, Richard H. Karas, William InsullJr.Jr., Michael Davidson & Eric J. Stanek. (2008) Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events. Journal of Clinical Lipidology 2:5, pages 343-353.
Crossref
Crossref
Peter H Jones, Harold E Bays, Michael H Davidson, Maureen T Kelly, Susan M Buttler, Carolyn M Setze, Darryl J Sleep & James C Stolzenbach. (2008) Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins. Clinical Drug Investigation 28:10, pages 625-634.
Crossref
Crossref
P. Lindgren, F. Borgström, J. Stålhammar, E. Alemao & L. Jönsson. (2007) Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs. International Journal of Clinical Practice 61:8, pages 1410-1414.
Crossref
Crossref